Ann: FOURTH SITE IN HEPATITIS C CLINICAL TRIAL, page-17

The problem is that before announcing patient 6 dosing, the company also stated they were no longer going to report on a per patient basis and that they would use "conventional" trial reporting standards. Then they proceeded to report that patient 6 was dosed shortly afterwards.

As we have been admonished again and again, this is a "first in man trial". It is also a trial that suffered greatly from dosing delays. Being a truly unique trial, it is not beyond reason to assume they could keep reporting on dosing. They have set it so they can do it either way once they contradicted themselves immediately after their last guidance about announcements concerning the trial.

As Hoyland said in regards to corrected announcement: Amateur hour. No value created pre-efficacy as other more experienced teams have readily done in the gene therapy space. They love to be the little bio that is always in the hole. They dug the hole, it's time to stop digging.

The announcement yesterday was as clear as mud.

Binary outcome is in play. Good luck to us all.